Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it Complete if Known Substitute for form 1449A/PTO 09/691,344 Ó **Application Number INFORMATION DISCLOSURE** Octob r 18, 2000 Filing Date First Named Inventor STATEMENT BY APPLICANT Donoho Group Art Unit 1632 Sheila Thomas **Examiner Name** se as many sheets as necessary 2 LEX-0071-USA of Attorney Docket Number Sheet JAN 25

				U.S. PATENT DOCUMEN	TS	
Examiner Initials*	Cite No.¹	U.S. Patent	Document	Name of Patentee or Applicant	Date of Publication	Pages, Columns, <b>LEGH CENTER</b> j Where Relevant Passages or Relevant
			Number	Kind Code <sup>2</sup> ( <i>if known</i> )	of Cited Document	of cited Document MM-DD-YYYY
Rh	AA	4,215,051		Schroeder et al	07/29/80	
2m	AB	4,376,110	-	David et al	03/08/83	
Ph.	/ AC	4,946,778		Ladner et al	08/07/90	
RM	AD	5,837,458		Minshull et al	11/17/98	
Rm	AE	5,869,336		Meyer et al	02/09/99	
Rh	AF	5,877,397		Lonberg et al	03/02/99	
2h	AG	6,075,181		Kucherlapati et al	06/13/00	

				FORE	IGN PATENT DOCUMENTS	3		
Examiner Initials*	Cite No.¹	Office <sup>3</sup>	Foreign Patent Docum		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	-							
			OTHER	PRIOR ART -	NON PATENT LITERATUR	RE DOCUMENTS		
Examine Initials*	ner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the							T <sup>2</sup>
RM.	AH-	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.						
RM	AI.	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.						
Rm'	AJ	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.						
Rh	AĶ	Gautier et a oxazolopyr 15(16):662	docarbazole. Sy	IV:α-anomeric nthesis, physio	and β-anomeric tetrathymid chemical properties and poly	ylates covalently linke y (rA) binding", Nuclei	d to intercalating c Acids Research	
RM	AL	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.						
Rh	1	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.						
Rhi	, AN		Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.					
Rh	AO		Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.					

		The state of the s	The second liverage of		7	
Examiner Signature	RITA	MITRA	Date Considered	9/	122/	102

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Subst	titute for form 1449B/PTO			Complete if Known			
INE	ORMATION I	אפור	CLOSURE	Application Number	09/691,344		
				Filing Date	Octob r 18, 2000		
STATEMENT BY APPLICANT				First Named Inv ntor	Donoho		
				Group Art Unit	1632		
	(use as many sheets	as nece	essary)	Examiner Name	Sheila Thomas		
Sheet	NPE	of	2	Attorney Docket Number	LEX-0071-USA		

<i>i</i>		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Ci <b>M</b> No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Rh	À	Arcids Research 15(15):6131-6149.	<u>ر</u>
Rhi	' AQ	Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.	
RM	AR	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS USA 88:8972-8976.	
Rh	AS	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
&m	AT	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	
Rh	AU	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	
RM	AV	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains"; Proc. Natl. Acad. Sci. USA 81:6851-6855.	
Rh	t AW	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
RM	ιĄΧ	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	
RM	⊦ AY	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
Am	AZ	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.	
RM	BA	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
RM	) BB	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
Rh	, BC	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
Rh	\ BD	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
RM	BE	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	I
RM	' BF	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	
RM.	BG	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.	
Rh,	, вн	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.	
Rh	BI	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.	
Rm	BJ	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.	
Kh	<sup>∨</sup> ВК	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232	

							_
Examiner Signature	717A	MITRA	Date Considered	9	122	02	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.